Industry
Biotechnology
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Loading...
Open
8.27
Mkt cap
541M
Volume
5.3M
High
8.54
P/E Ratio
-4.67
52-wk high
14.84
Low
7.46
Div yield
N/A
52-wk low
2.38
Portfolio Pulse from
November 06, 2024 | 12:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 12:26 pm
Portfolio Pulse from Vandana Singh
October 11, 2024 | 6:11 pm
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 11:38 am
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 5:14 pm
Portfolio Pulse from Benzinga Insights
August 22, 2024 | 6:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 5:40 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 6:44 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 3:12 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.